ANNX Jul 2024 7.500 put
| Previous Close | 4.2000 |
| Open | 4.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 4.2000 - 4.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksDown -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksAre Medical Stocks Lagging Annexon (ANNX) This Year?
Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
GlobeNewswireAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the ag
